Articles tagged with Tau Proteins
Researchers are modifying an arm of a worldwide clinical trial to evaluate a combination of drugs targeting two brain proteins: amyloid and tau. The Tau NexGen Trial aims to test the effectiveness of these treatments in slowing disease progression by targeting both Alzheimer's disease pathologies.
Researchers found that glatiramer acetate improved cognitive behavior and reduced amyloid plaques in a mouse model of Alzheimer's disease. This study suggests therapies targeting the immune system could be effective in treating the disease.
Researchers found that Alzheimer's disease develops by replicating aggregates in individual brain regions, rather than spreading them. The study used human data and PET scans to track the aggregation of tau protein, a key player in the disease.
Scientists at Gladstone Institutes discovered that non-convulsive epileptic activity drives chronic brain inflammation in Alzheimer's models, which can be reversed by eliminating protein tau or using the anti-epileptic drug levetiracetam. This link between brain networks and immune cells may hold promising treatments for Alzheimer's di...
Researchers at Gladstone Institutes found that reducing tau levels impacts both excitatory and inhibitory cells, leading to a reduction in excitation-inhibition ratios. This effect counteracts diseases that cause abnormal increases in this ratio, potentially improving the brain's ability to perform its functions.
Michel Goedert's research focuses on protein aggregates in Alzheimer's and Parkinson's, providing deep insights into disease development. His work is essential for finding new treatments, as evidenced by his discovery of gene mutations leading to dementia.
Researchers have developed a novel mouse model that accurately replicates the pathological propagation of tau protein isoforms in Alzheimer's disease, corticobasal degeneration, and Pick's disease. The model shows endogenous expression of both 3R and 4R tau, which accumulates in brain regions characteristic of each disease.
Researchers found that early accumulation of tau proteins in the brain, measured by PET scanner, is more effective at predicting memory impairment than other biomarkers. The study suggests that tau PET should be recommended for clinical prognostic assessment of cognitive decline in Alzheimer's patients.
Researchers have developed a potential blood test to diagnose Alzheimer's disease using atomic force microscopy technology. The test analyzes protein fibers made up of beta-amyloid peptides and tau proteins, which accumulate in patients' blood cells, indicating the stage of the disease.
Scientists have found that misfolded tau protein accumulates RNA tags called N6-Methyladenosine (m6A) in nerve cells, leading to neurodegeneration. Inhibiting this RNA-tagging pathway shows promise as a potential approach to treat Alzheimer's disease.
Georgia State University researcher Vince Calhoun has received a $3.5 million grant to develop new methods for capturing dynamic connectivity in the brain and identifying biomarkers for early detection of Alzheimer's disease. The researchers aim to analyze real-time connectivity patterns to predict future cognitive decline.
A study found a significant association between higher tau concentrations and lower physical activity with increased cognitive decline rates in individuals with Alzheimer's disease. The research suggests that increasing physical activity may help slow cognitive decline.
Researchers discover that a slightly acidic environment is conducive to the formation of Alzheimer's disease-causing toxic protein aggregates, known as Aβ oligomers. The study also reveals that endosomes and lysosomes play a crucial role in their development.
Researchers at Tokyo Metropolitan University have discovered that disulfide bonds on certain amino acids stabilize tau protein, leading to its accumulation and triggering neurodegenerative diseases like Alzheimer's. The study suggests that targeting these chemical groups may lead to novel treatments to reduce or prevent tau accumulation.
A new international study has identified a drug that can halt the progression of chronic traumatic encephalopathy (CTE) in sportspeople who sustain repeated head injuries. The treatment was successfully tested in animal models and shows promise for preventing neurological problems associated with CTE, which affects cognition and behavior.
Understanding how tau protein is regulated in brain cells could lead to better treatments for Parkinson's and other neurological conditions. Researchers discovered that similar lncRNAs control the production of tau and other key proteins involved in brain function.
Researchers identify 'antisense long non-coding RNA' regulating tau protein production, a crucial mechanism for brain cell function. The discovery may lead to new treatments for dementia-related diseases, including Parkinson's and Alzheimer's.
Researchers discovered a correlation between decreased Rbbp7 levels and increased tau protein tangle formation in Alzheimer's brains. Restoring Rbbp7 levels reversed tangle formation and cell loss, offering a new avenue for effective treatments.
Scientists have found that a Mediterranean-like dietary pattern with high intake of vegetables, legumes, and fish may reduce protein deposits in the brain and prevent brain atrophy. The study suggests that adhering to this diet could lower the risk of Alzheimer's disease and dementia.
A University of Colorado Boulder study reveals that tau aggregates interfere with RNA splicing, leading to neurodegeneration in Alzheimer's disease and other tauopathies. The findings provide new insights into the mechanism of action of tau tangles, shedding light on potential therapeutic targets.
Research from Lund University in Sweden suggests that women accumulate Alzheimer's-related protein tau at a higher rate than men. The study found a 75% higher accumulation rate of tau in women compared to men in the temporal lobe affected by the disease.
A new gene regulation therapy using zinc finger proteins has shown high efficacy in reducing Tau protein levels in the brain, potentially protecting against Alzheimer's disease. The treatment reduces Tau production by 50-80% and prevents nerve damage without obvious side effects.
Researchers have developed a new animal model of early-stage Alzheimer's disease in rhesus macaques, which could enable better testing of new treatments. The model replicates the spread of misfolded tau proteins through brain circuits, similar to human disease progression.
Tau oligomers form droplets within TIA1 droplets selectively, producing highly lethal effects on neurons. The study provides a tool to screen compounds that can inhibit tau oligomer formation, offering hope for Alzheimer's and frontotemporal dementia treatment.
A study by University of Liège researchers links increased tau protein levels in the brainstem to higher cortical excitability, a hallmark of Alzheimer's disease. The findings suggest that measuring cortical hyperexcitability could help identify people at risk before cognitive symptoms appear.
A new study has made a significant discovery about the origins of TAU protein in Alzheimer's disease, revealing its primary emergence in the rhinal cortex. The automated method, which tracks TAU buildup using PET imaging, suggests targeting this area could slow disease progression.
A study published in Proceedings of the National Academy of Sciences reveals that liquid-liquid phase separation facilitates tau protein aggregation, a hallmark of neurodegenerative disorders. The researchers discovered a novel regulatory mechanism involving different variants of tau protein, which may influence disease clinical outcomes.
Research reveals that tau protein undergoes stepwise chemical modifications over time, correlating with dementia stage in Alzheimer's disease. The discovery suggests that multiple drugs may be necessary to target tau effectively, with early intervention requiring different therapeutics compared to late-stage treatment.
Researchers have developed an antibody fragment that reduces Aú peptide and tau protein levels, alleviating cognitive decline and neuroinflammation in advanced Alzheimer's disease models. This breakthrough therapy shows promise as a potential treatment for the devastating disease.
A study by Tokyo Metropolitan University reveals that a specific MARK4 mutation causes tau protein to aggregate in the brain, leading to Alzheimer's disease. The mutated enzyme makes tau proteins sticky and insoluble, causing neurons to die and memory functions to impair.
Researchers discovered a novel mutation in the VCP gene leading to a buildup of tau proteins and neuronal vacuoles, characteristic of Vacuolar Tauopathy (VT), a rare neurodegenerative disease. The study suggests a new therapeutic target for Alzheimer's disease by boosting VCP activity to break up protein aggregates.
A new mouse model shows that injecting synthetic assembled tau protein causes tau accumulation in wild-type mice, spreading to connected regions. This study establishes that tau assembly does not require mutation or overexpression.
Researchers discovered a novel role of tau specific to FTLD spectrum diseases, contributing to conditions like ALS, PSP, and CBD, but not AD and Pick's disease. The study proposes an imbalanced accumulation of tau model, where FUS and SFPQ regulate MAPT processing, leading to increased 4-repeat tau levels.
A new study has uncovered 12 proteins linked to both tau and Alzheimer's disease, expanding understanding of the molecular interactions driving neurodegeneration. The research analyzed donated brain tissue samples from individuals with Alzheimer's, revealing dozens of other proteins associated with the disease.
Researchers discovered deposits of the tau protein typically found in Alzheimer's patients in the brain of an autistic child with ADNP syndrome. An experimental drug called NAP successfully restored normal function to damaged nerve cells in models of ADNP syndrome, offering new hope for treating this genetic disorder.
A new study sheds light on the molecular factors that render entorhinal brain cells uniquely sensitive to degeneration. Researchers found that a suite of genes is likely involved in making these neurons easy targets for degeneration, with PTBP1 playing a major role.
Researchers found that neurons with high remodeling activity are more vulnerable to Alzheimer's disease and die when their remodeling goes awry. The study, which linked amyloid-beta and tau proteins at the genetic and molecular levels, provides insights into the disease's progression.
A new study from Massachusetts General Hospital reveals that different forms of phosphorylated tau can explain variable effects in Alzheimer's disease. The research found specific molecular characteristics associated with greater tau spread and worse disease progression.
Researchers at Lund University and McGill University found that toxic tau protein spreads in the human brain via connected neurons, facilitated by beta-amyloid. The spread of toxic tau leads to widespread neuronal death and eventual dementia.
A study published in Nature reveals that the low-density lipoprotein receptor-related protein 1 (LRP1) plays a key role in the spread of pathological tau proteins between neurons. By inhibiting LRP1 expression, researchers were able to reduce tau spread in mice, offering new hope for potential treatments.
Researchers from University of Konstanz discover that a molecular chaperone helps form Alzheimer fibrils by exposing a vulnerable area on the protein tau, preventing longer, more toxic fibril formation. The findings suggest a possible defense mechanism against Alzheimer's disease.
A study of 754 participants found that specific gene variants on chromosomes 1 and 5 were associated with higher levels of tau protein in the brain. These variants were present in around 2-3% of the group, leading to about 10% higher tau levels than those without.
A Mayo Clinic study found that genetic variants on chromosomes 1 and 5 were linked to higher tau levels in older adults. Participants with these variants had about 10% higher tau levels than those without them. The research suggests that genes previously linked to Alzheimer's risk may not be associated with tau accumulation.
A new brain scan-blood test panel has been developed to help diagnose brain trauma following battlefield blasts. The panel combines functional assessment with blood tests and brain scans to estimate brain degeneration in human veterans exposed to IED blasts.
The Kong group will investigate how neurons and muscle cells communicate, with the goal of understanding how to reactivate neurons in injured muscle. They will also develop a drug delivery system to target tau proteins responsible for Alzheimer's disease.
A University of South Florida study suggests beta-arrestin-2 can lead to increased accumulation of neurotoxic tau tangles in the brain, causing forms of dementia. The researchers found that oligomerized beta-arrestin-2 disrupts protective clearance processes, leading to disease-causing tau buildup.
Researchers analyzed brain tissue from patients with Alzheimer's and corticobasal degeneration, finding that modifications to the tau protein influence its misfolding behavior. The study reveals key insights into how tau filaments form, grow, and spread throughout the brain, potentially accelerating the fight against neurodegenerative ...
Tau proteins exhibit distinct aggregation behaviors, with phosphorylation influencing their formation of either solid fibrils or disordered clumps. The researchers' findings offer new insights into the causes of Alzheimer's and frontotemporal dementia, potentially leading to the development of therapeutic interventions.
A study on globular glial tauopathy reveals that phosphate groups are not unique to tau protein and can lead to dysfunction in other proteins. Glial cells also play a crucial role in the disease's progression by facilitating the spread of protein inclusions. This research sheds light on potential new drug targets to stop disease progre...
Researchers found that reelin promotes synaptic plasticity and reduces Tau phosphorylation in animal models with tauopathy, potentially reducing neurodegenerative effects. This discovery opens a new perspective for designing future therapeutic targets to combat Alzheimer's and other tauopathies.
Researchers found that inflammatory processes triggered by the NLRP3 inflammasome play a key role in emerging tau pathology, a hallmark of neurodegenerative diseases like Alzheimer's. The study suggests that modulating the immune response could be a promising approach for treating these conditions.
Scientists have linked abnormal tau in the brain to at least 25 neurodegenerative diseases, but current diagnosis requires analyzing brain tissue after death. The new test uses cerebrospinal fluid to detect abnormal tau, offering hope for diagnosing less common neurological diseases like Alzheimer's.
University of Warwick researchers introduce fluorescently labelled Tau oligomers into single brain neurons and observe significant effects on action potential dynamics and synaptic transmission. They find that Tau oligomers interfere with memory storage by mis-localising at synapses.
Researchers at Imperial College London visualized protein 'tangles' associated with dementia in patients who suffered a single head injury, showing collective likelihood of tau tangles and nerve damage. The study may accelerate treatment development by enabling medics to monitor tau protein levels.
Researchers at UC San Francisco have found that Alzheimer's disease directly attacks brain regions responsible for wakefulness during the day, leading to excessive daytime napping. This damage is associated with tau protein buildup, which contributes more directly to brain degeneration than amyloid protein.
A new skin test using ultrasensitive technology may provide an early diagnosis of Alzheimer's and Parkinson's diseases, detecting misfolded proteins in skin samples. The RT-QuIC test is highly sensitive and specific, offering a promising tool for diagnosing and characterizing these neurodegenerative diseases.
The study reveals that Tau controls Fyn nanoclustering in dendrites, leading to altered nerve signals and synapse dysfunction. Single molecule imaging provides unprecedented insights into the organisation of key proteins in living brain cells.
Researchers have identified non-inherited somatic mutations in the brain that could contribute to Alzheimer's disease progression. These mutations were found to be associated with hyperphosphorylation of tau proteins, a hallmark of AD.
Researchers at Temple University Health System discovered that VPS35 clears the brain of a potentially harmful protein called tau, which accumulates in neurodegenerative disorders. The study found that altering VPS35 levels in individual neurons can directly control tau accumulation, implicating VPS35 in tauopathy.
Research finds that older brains have a higher rate of tau protein spread, contributing to Alzheimer's disease progression. The study uses gene vectors to demonstrate this connection in mice, raising questions about therapeutic options and disease mechanisms.